Skip to main content
Donate

Industry

News

Oak Hill Bio: A Message to the Angelman Syndrome Community

Following the recent announcement on the outcome of the phase 3 Aspire trial of GTX-102, Oak Hill Bio has shared a message about their commitment to evaluate rugonersen in their ongoing Phase 3 BEACON trial.

Read the letter here

Related

Ultragenyx Announces Phase 3 Aspire results in Angelman Syndrome
Update on CHAMPION, Phase 3 clinical trial of ION582 (obudanersen)
Rugonersen Development Update: First Participant Dosed in the Phase 3 BEACON Trial
Ionis completes enrollment in pivotal cohort of the Phase 3 REVEAL study evaluating obudanersen in Angelman syndrome

View All News

Disclaimer

This website contains information for a broad audience and may include information on current and upcoming programs that are not yet approved or accessible The information provided is for general informational purposes only and is not intended as medical advice, diagnosis, or treatment. While FAST strives to provide accurate and up-to-date information, the content on this site may not always reflect the most current research or clinical guidelines. The inclusion of clinical trial information, treatments or specific healthcare providers does not imply endorsement, recommendation or guarantee of safety, efficacy, or availability. Reliance on any information provided by this website is solely at your own risk. FAST disclaims any liability for any errors or omissions in the information provided or for any decisions made based on this information. For personalized medical advice or specific health concerns including participation in any clinical trial, please consult a qualified healthcare professional.